MYC and melanoma: To test the anti-tumor effects of a novel antisense oligodeoxynucleotide (ODN) liposomal formulation, the coated cationic liposomes (CCLs), through the use of a monoclonal antibody against the disialoganglioside GD2, Pastorino et al performed an in vitro and in vivo study by targeting C-MYC in melanoma.